Directory
Xavier Matias-Guiu Guia

Xavier Matias-Guiu Guia

Degree: PhD

973 705 340
fjmatiasguiu.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3039-2009

Groups

Publications

  • Huerva V; Soldevila J; Matias-Guiu X

    Recurrent Amyloid Material in Grafts Used in Patients with Lattice Corneal Dystrophy 2 (Meretoja's Syndrome).

    Medical hypothesis, discovery and innovation in ophthalmology 3 99-100. .

  • Matias-Guiu, X.

    Endometrial carcinoma: Pathological and molecular features

    Endometrial Carcinoma: Pathological And Molecular Features 59-81. .

  • Castelblanco, Esmeralda; Santacana, Maria; Valls, Joan; de Cubas, Aguirre; Cascon, Alberto; Robledo, Mercedes; Matias-Guiu, Xavier

    Usefulness of Negative and Weak-Diffuse Pattern of SDHB Immunostaining in Assessment of SDH Mutations in Paragangliomas and Pheochromocytomas

    ENDOCRINE PATHOLOGY 24 199-205. .

    [doi:10.1007/s12022-013-9269-4]

  • Barlin JN; Soslow RA; Lutz M; Zhou QC; St Clair CM; Leitao MM; Iasonos A; Hensley ML; Barakat RR; Matias-Guiu X; Abu-Rustum NR

    Redefining Stage I Endometrial Cancer Incorporating Histology, a Binary Grading System, Myometrial Invasion, and Lymph Node Assessment

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 23 1620-1628. .

    [doi:10.1097/IGC.0b013e3182a5055e]

  • Romero-Perez, Laura; Angeles Lopez-Garcia, M.; Diaz-Martin, Juan; Biscuola, Michele; Angeles Castilla, M.; Tafe, Laura J.; Garg, Karuna; Oliva, Esther; Matias-Guiu, Xavier; Soslow, Robert A.; Palacios, Jose

    ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma

    Modern Pathology 26 1514-1524. .

    [doi:10.1038/modpathol.2013.93]

  • Das, Arindam; Pushparaj, Charumathi; Herreros, Judit; Nager, Mireia; Vilella, Ramon; Portero, Manuel; Pamplona, Reinald; Matias-Guiu, Xavier; Marti, Rosa M.; Canti, Carles

    T-type calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells

    PIGMENT CELL & MELANOMA RESEARCH 26 874-885. .

    [doi:10.1111/pcmr.12155]

  • Mirantes C; Espinosa I; Ferrer I; Dolcet X; Prat J; Matias-Guiu X

    Epithelial-to-mesenchytnal transition and stem cells in endometrial cancer

    HUMAN PATHOLOGY 44 1973-1981. .

    [doi:10.1016/j.humpath.2013.04.009]

  • Diaz-Padilla, Ivan; Romero, Nuria; Amir, Eitan; Matias-Guiu, Xavier; Vilar, Eduardo; Muggia, Franco; Garcia-Donas, Jesus

    Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and meta-analysis

    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 88 154-167. .

    [doi:10.1016/j.critrevonc.2013.03.002]

  • Eritja, Nuria; Dolcet, Xavier; Matias-Guiu, Xavier

    Three-dimensional epithelial cultures: a tool to model cancer development and progression

    HISTOLOGY AND HISTOPATHOLOGY 28 1245-1256. .

    [doi:10.14670/HH-28.1245]

  • Herranz, D.; Maraver, A.; Canamero, M.; Gomez-Lopez, G.; Inglada-Perez, L.; Robledo, M.; Castelblanco, E.; Matias-Guiu, X.; Serrano, M.

    SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency

    ONCOGENE 32 4052-4056. .

    [doi:10.1038/onc.2012.407]

  • Bergadà L; Sorolla A; Yeramian A; Eritja N; Mirantes C; Matias-Guiu X; Dolcet X

    Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells

    MOLECULAR ONCOLOGY 7 763-775. .

    [doi:10.1016/j.molonc.2013.03.003]

  • Eritja N; Mirantes C; Llobet D; Yeramian A; Bergadà L; Dosil MA; Domingo M; Matias-Guiu X; Dolcet X

    Long-Term Estradiot Exposure Is a Direct Mitogen for Insulin/EGF-Primed Endometriat Cells and Drives PTEN Loss-Induced Hyperplasic Growth

    AMERICAN JOURNAL OF PATHOLOGY 183 277-287. .

    [doi:10.1016/j.ajpath.2013.03.008]

Projects

  • Homologous recombination deficiency in high-grade endometrial cancers. Biomarkers and impact of intratumor heterogeneity.
  • EPH Receptor Signaling in Endometrial Cancer
  • Ajuts per a la contractació de personal investigador novell (FI)
  • Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
  • "Multi-Omics data for Cancer Research and the Development of New Diagnostics and Therapies"
  • EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
  • Incorporación de nuevas areas temáticas y nuevos grupos al consorcio CIBER
  • Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
  • CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI
  • DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
  • Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cancer ginecológico (PREDICTGYN)
  • VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU